Sanofi Says Late-Stage Trial of Type 2 Drug a Success

7162

French drug maker Sanofi-aventis says that results from a Phase III trial of its experimental type 2 diabetes drug lixisenatide show that the drug successfully lowered patients’ blood glucose levels and body weight, but did not increase the risk of hypoglycemia.

Lixisenatide is a GLP-1 agonist, one of a family of drugs that work by stimulating the release of insulin when blood sugar levels rise too high.

The Phase III study tracked 361 type 2 patients with A1C levels between 7% and 10% who were not receiving any therapy for blood glucose. The patients were divided into three groups, two that took once-daily doses of the drug at different levels of strength, and a third that received a placebo. The test lasted 12 weeks.
 
Sanofi says that the two groups taking the experimental drug experienced “significantly reduced” A1C levels-including levels below 7%-and “significantly improved” fasting plasma glucose and two-hour post-meal glucose.  

If lixisenatide gains FDA approval to go to market, it will join a field of GLP-1 agonists that includes Amylin and Eli Lilly’s Byetta (exenatide) and Novo Nordisk’s Victoza (liraglutide). Financial analysts say the drug could carve out a $500 million niche in the U.S. market.

Click here to view/write comments
Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.